Avacta Group launch of SARS-CoV-2 BAMS research test

Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that the BAMS assay to detect the SARS-CoV-2 virus has been launched as a research kit1 by its partner Adeptrix (Beverly, MA, USA) and the assay has been presented by Bruker Scientific (Billerica, MA, USA), a leading mass spectrometer manufacturer, in a new application note2.

The bead-assisted mass spectrometry assay uses the Affimer reagents specific to the SARS-CoV-2 virus to capture the virus spike protein from the sample for rapid detection by mass spectrometry, using the installed base of these instruments in hospitals. Up to one thousand samples per day can be analysed by a single technician using BAMS, making BAMS a very attractive high throughput technique for COVID-19 diagnosis and research.

Adeptrix has launched a BAMS research assay kit incorporating Avacta’s Affimer reagents in order to make this powerful tool available to researchers globally to support the fight against the coronavirus. Work carried out in parallel by Bruker, a leading mass spectrometer manufacturer with a significant installed base of instruments in hospitals globally, to assess the performance of the assay has been published by Bruker in a detailed application note.

Avacta continues to work actively with the UK government’s CONDOR programme to clinically evaluate the coronavirus BAMS assay in order to obtain regulatory approval for diagnostic use. Avacta and Adeptrix are in discussions with mass spectrometer manufacturers with a view to establishing commercial partnerships to market the research use and diagnostic products.

Commercial details are not being disclosed but Avacta will receive a royalty on the SARS-CoV-2 BAMS research kit sales.

1. https://adeptrix.com/store#!/SARS-CoV-2-S1-GlycoproteinAssay/p/234586062/category=0 

2. https://www.bruker.com/fileadmin/user_upload/8-PDF-Docs/Separations_MassSpectrometry/Literature/ApplicationNotes/1881181_MT-128_SARS-CoV-2_Antigen_Assay_ebook.pdf

Alastair Smith, Chief Executive Officer of Avacta Group, commented:

“I am delighted that the Affimer-based BAMS assay developed with Adeptrix is now available for scientists to use in their research into the coronavirus. A research use assay is the first step in commercialising this powerful Affimer-based coronavirus research and diagnostic tool and the clinical evaluation of the assay in the UK to support CE marking for diagnostic use is a very high priority for Avacta.

I am also very pleased indeed that Bruker has published their application note, providing considerable detail about the performance of the SARS-CoV-2 BAMS assay, clearly demonstrating the potential of this Affimer-based coronavirus mass spectrometry test and another important validation of the Affimer platform.

I look forward to updating the market on the clinical evaluation of the BAMS assay and on commercial progress in due course.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta Group shortlisted for Biotech Company of the Year

The finalists in the 2020 Cambridge Independent Science and Technology Awards can now be revealed. Following hundreds of entries, a shortlist across 14 categories has been drawn up. Biotech Company of the Year, sponsored by Appleyard Lees Avacta

Avacta Group Plc

Avacta and COVID-19

Avacta is supporting global efforts in combating the COVID-19 pandemic by using its Affimer®  platform to develop diagnostic reagents for COVID-19 ANTIGEN testing. Avacta has generated a large number of Affimer binders to the SARS-COV-2 virus

Avacta Group Plc

Elisa test launch

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech

Avacta Group Plc

Cytiva strengthens support to diagnostics industry

Cytiva launches new services for diagnostic developers and will establish new labs to meet the future needs of the industry. Cytiva Diagnostic Services will help developers bring point-of-care diagnostic tests to market quicker through infrastructure, expertise and consultation for

Avacta Group Plc

Avacta set for “momentous milestones”

The Wetherby-based firm hopes to get the test, which works like a pregnancy test but uses saliva, validated before the end of 2020, which could be a game changer for the UK’s testing capability. Analyst Mark

Avacta Group Plc

‘Transformational’ year ahead for Avacta Group

Avacta Group’s CEO predicts a “transformational year” ahead with “momentous milestones” for the company as it progresses its Covid-19 test and other products. The Whittlesford-based drug development company unveiled interim results for the six months to

Avacta Group Plc

Avacta hails “period of significant advancement”

Listed biotechnology business Avacta Group has hailed a “period of significant advancement” in its interim results, with “several momentous milestones” now on the horizon. The company, which as sites in Wetherby and Cambridge, reported revenue of

Avacta Group Plc

Avacta Group appoints Stifel Nicolaus Europe as joint broker

Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced the appointment of Stifel Nicolaus Europe Limited as joint broker with immediate effect.

Avacta Group Plc

Avacta Group “a period of significant advancement”

Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced its unaudited interim results for the six-month period ended 30 June 2020. Operating highlights Avacta

Avacta Group Plc

More progress unveiled in collaboration against Covid-19

York-based life sciences business Integumen has announced progress on its COVID-19 wastewater detection system, Microtox PD, in collaboration with Modern Water plc, Avacta Group and Aptamer Group Limited.  Integumen is working with a consortium of companies